After having 17 melanoma spots removed, ‘Real Housewives of Beverly Hills’ alum Teddi Mellencamp was diagnosed with multiple ...

The combination therapy failed to beat out the company’s other cancer therapy, Opdivo, in patients living with melanomas.

Upon Opdualag’s approval in 2022 as a first-in-class cancer immunotherapy, Bristol Myers Squibb was anxious to explore its potential in a variety of indications. | Bristol Myers Squibb is striking out ...

University of Queensland researchers have discovered immunotherapy, when used to treat people with advanced cancers, also ...

Iowa has the fastest-growing rate of new cancers and ranks second-highest in cancer rates compared to other states, according ...

University of Queensland researchers have discovered immunotherapy, when used to treat people with advanced cancers, also ...

Opdualag is a fixed-dose combination of nivolumab, a programmed death receptor-1 blocking antibody, and relatlimab, a lymphocyte activation gene 3 blocking antibody.

Bristol Myers Squibb today announced the Phase III RELATIVITY-098 trial evaluating Opdualag (nivolumab and relatlimab-rmbw) ...

U.S. Food and Drug Administration (FDA) recently accepted the Biologics License Application (BLA) for RP1 plus nivolumab in advanced melanoma for ...

University of Queensland research using natural killer cells may lead to the first new treatment for a devastating childhood ...